Euro falls against Canadian Dollar amid French debt fears, oil rally
EUR/CAD continues its losing streak for the fourth successive day, trading around 1.5940 during European hours on Thursday. The currency cross has depreciated as the Euro (EUR) faces ongoing pressure driven by fiscal instability in France and broader contagion fears across the Eurozone.
Concerns over Paris's ability to rein in its budget deficit triggered a sharp bond market selloff, driving the risk premium on French government debt to its highest level since the Eurozone debt crisis. As investors shed French bonds in favor of safer German bunds, French Prime Minister Sébastien Lecornu's minority government announced a €54bn savings package last month to avert a catastrophic credit downgrade or sovereign default.
Adding to the Euro's headwinds, Germany’s Trade Surplus narrowed to €19.5 billion in August from a revised two-and-a-half-year high of €21.6 billion in July, though it slightly topped market expectations of €19 billion. The narrowing was driven by an unexpected 0.8% month-on-month drop in exports, defying forecasts for a 0.8% increase, alongside a 0.9% rebound in imports following a steep decline in the prior month.
Meanwhile, the EUR/CAD cross remains under pressure as the commodity-linked Canadian Dollar (CAD) benefits from a surge in global crude oil prices. Energy markets rallied on reports that the Trump administration directed the Pentagon to draft military strike options against Iran ahead of the US midterm elections, confounding expectations of a pre-election de-escalation.
Oil prices received further upward momentum from supply disruptions in the Gulf of Mexico caused by Tropical Storm Isaias. Offshore producers were forced to shut in over 510,000 barrels per day of crude production, taking approximately a quarter of the region’s total output offline and offering additional support to the CAD.
Canada faces rising political fragmentation as separatist risks resurface
Analysts at Rabobank highlight growing political strains in Canada, noting that “the separatist Parti Québécois won around 30 percent of the vote in Monday’s provincial election, gaining 59 of 127 seats—just shy of a majority but enough to form a minority government.” They add that the picture is complicated further by developments in the west, where “Alberta will vote on its own independence (or at least, the process to start considering independence) from Canada on October 19,” underscoring a rise in regional fragmentation that could add to the country’s political risk profile.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Atrium Therapeutics shares surge after completing $50 million equity financing
On October 8, shares of heart disease drug developer Atrium Therapeutics (RNA.O) rose 11.3% to $8.83 in pre-market trading on Thursday after the company successfully raised $50 million. The biopharmaceutical company announced it has agreed to sell about 6.3 million shares and pre-funded warrants to institutional investors through a private placement at $7.93 per share. RNA’s shares closed down 0.8% at $7.93 on Wednesday and have fallen roughly 44% in the past month. The company plans to use the net proceeds for the development of its two main product candidates, other research projects, among other uses. Atrium expects that the funds raised, together with existing cash and investments, will be sufficient to support its operations through 2028. Leerink acted as the lead placement agent for this offering, with Cantor Fitzgerald, Barclays, and Wells Fargo participating as well. Based in San Diego, California, Atrium has signed collaboration agreements with Bristol Myers Squibb (BMY.N) and Eli Lilly (LLY.N), and has about 17.1 million shares outstanding. Atrium began public trading on February 27 (link), following a spinoff from Avidity Biosciences (link), which was subsequently acquired by Swiss pharmaceutical company Novartis (NOVN.S).
BUZZ - Henry Schein shares fall after appointing new Chief Financial Officer
October 8 - ** Shares of dental products distributor Henry Schein (HSIC.O) dropped 2% to $82 in pre-market trading. ** Ronald South, who has served as CFO for the past four years, will transition to Senior Advisor. ** Emmanuel Caprais will take over as CFO, officially assuming the role on November 4. ** Caprais was previously the Chief Financial Officer of global industrial manufacturer ITT. ** This leadership change comes about seven months after Frederick Lowery succeeded Stanley Bergman as CEO; Bergman had led the company for 35 years. ** Among 18 brokers, 9 rate the stock as “buy” or above, 8 as “hold”, and 1 as “sell”; the median target price is $96—data compiled by LSEG. ** As of the previous trading day's close, the stock has risen 10.69% year-to-date.
Movado to Sell 95% Stake in EBEL Luxury Watch Brand for $66.5 Million
07:34 AM EDT, 10/08/2026 (MT Newswires) -- Movado (MOV) said Thursday that it has agreed to sell a 95% stake in its EBEL luxury watch brand for $66.5 million to a group led by Montres Journe, with participation from Chanel and Pierre Jacques. The deal enables Movado to deepen its focus on its core luxury and fashion watch and jewelry products, it said. Movado said it will initially transfer EBEL's intellectual property, inventory, and certain other assets to a newly formed Swiss unit, while retaining a 5% stake in the business. The transaction, expected to close in the next few months, is subject to adjustments and closing conditions, the company said.
Hydreight makes C$ 300,000 strategic investment in Insu Therapeutics
Hydreight Technologies disclosed a C$ 300,000 minority investment in Insu Therapeutics, completed on March 13, 2026. The deal also granted Hydreight U.S. distribution rights for peptide medicines using Insu’s buccal delivery technology, subject to development success. Insu received a USPTO Notice of Allowance on a buccal peptide-delivery patent application, reinforcing Hydreight’s strategic stake. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hydreight Technologies Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610080730CANADANWCANADAPR_C0229) on October 08, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
